483 related articles for article (PubMed ID: 26023014)
1. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
Shigematsu T; Ohya M; Negi S; Masumoto AR; Nakashima YM; Iwatani Y; Moribata MK; Yamanaka S; Tatsuta K; Mima T
Contrib Nephrol; 2015; 185():42-55. PubMed ID: 26023014
[TBL] [Abstract][Full Text] [Related]
2. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
[TBL] [Abstract][Full Text] [Related]
3. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
4. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
Negi S; Shigematsu T
Clin Calcium; 2010 Jul; 20(7):1096-102. PubMed ID: 20585189
[TBL] [Abstract][Full Text] [Related]
5. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
6. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Shigematsu T;
Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
[TBL] [Abstract][Full Text] [Related]
7. Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
Guo H; Zhang X; Tang S; Zhang S
Ren Fail; 2013; 35(10):1455-64. PubMed ID: 23992043
[TBL] [Abstract][Full Text] [Related]
8. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
Ogata H; Fukagawa M; Hirakata H; Kagimura T; Fukushima M; Akizawa T;
JAMA; 2021 May; 325(19):1946-1954. PubMed ID: 34003226
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
Shigematsu T; Negi S;
Nephrol Dial Transplant; 2012 Mar; 27(3):1050-4. PubMed ID: 21771755
[TBL] [Abstract][Full Text] [Related]
10. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
11. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
[TBL] [Abstract][Full Text] [Related]
12. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic use of the phosphate binder lanthanum carbonate.
Barton Pai A; Conner TA; McQuade CR
Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):71-81. PubMed ID: 19236230
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
15. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
Cozzolino M; Brancaccio D
Int J Artif Organs; 2007 Apr; 30(4):293-300. PubMed ID: 17520565
[TBL] [Abstract][Full Text] [Related]
16. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
Mohammed I; Hutchison AJ
J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
[TBL] [Abstract][Full Text] [Related]
17. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
[TBL] [Abstract][Full Text] [Related]
18. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2008 Feb; 12(1):55-61. PubMed ID: 18257813
[TBL] [Abstract][Full Text] [Related]
19. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
20. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
Shigematsu T; Tokumoto A; Nakaoka A; Arisaka H
Ther Apher Dial; 2011 Apr; 15(2):176-84. PubMed ID: 21426511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
